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A B S T R A C T
Background: Course of illness in major depression (MD) is highly varied, which might lead to both under- and
overtreatment if clinicians adhere to a 'one-size-fits-all' approach. Novel opportunities in data mining could lead
to prediction models that can assist clinicians in treatment decisions tailored to the individual patient. This study
assesses the performance of a previously developed data mining algorithm to predict future episodes of MD
based on clinical information in new data.
Methods: We applied a prediction model utilizing baseline clinical characteristics in subjects who reported
lifetime MD to two independent test samples (total n = 4226). We assessed the model's performance to predict
future episodes of MD, anxiety disorders, and disability during follow-up (1–9 years after baseline). In addition,
we compared its prediction performance with well-known risk factors for a severe course of illness.
Results: Our model consistently predicted future episodes of MD in both test samples (AUC 0.68–0.73, modest
prediction). Equally accurately, it predicted episodes of generalized anxiety disorder, panic disorder and dis-
ability (AUC 0.65–0.78). Our model predicted these outcomes more accurately than risk factors for a severe
course of illness such as family history of MD and lifetime traumas.
Limitations: Prediction accuracy might be different for specific subgroups, such as hospitalized patients or pa-
tients with a different cultural background.
Conclusions: Our prediction model consistently predicted a range of adverse outcomes in MD across two in-
dependent test samples derived from studies in different subpopulations, countries, using different measurement
procedures. This replication study holds promise for application in clinical practice.
1. Introduction
The course of major depression (MD) can be highly varied
(Eaton et al., 2008), which may lead to either over- or undertreatment
in clinical practice if a generic treatment regimen is adopted. Data
mining techniques offer opportunities to develop prediction algorithms
for clinically relevant outcomes such as course of illness (Hastie et al.,
2009). Data mining uses pattern recognition techniques to extract im-
portant patterns and trends from data, for example with the aim to
predict outcomes. If sufficiently accurate, the resulting prediction
models could assist clinicians in identifying patients with a distinct
course of illness, and thus support more specific treatment allocation
(Darcy et al., 2016), for instance on decisions whether to continue or
discontinue treatment after recovery of MD. In different medical dis-
ciplines, these opportunities are now being explored (Jiang et al.,
2017), in order to move from a ‘one-size-fits-all’ approach to treatment
assignments that are more tailored to the individual patient.
Also in psychiatry, scientists have started to leverage data mining
for patient care. Several previous studies developed algorithms to pre-
dict course-related outcomes in MD, such as recurrence of MD
(van Loo et al., 2015; Wang et al., 2014), treatment resistance or re-
mission (Chekroud et al., 2016; de Vries et al., 2018; Perlis, 2013), or
episode persistence, chronicity, hospitalization and disability
(van Loo et al., 2014a; Wardenaar et al., 2014). However, most studies
were limited by the use of relatively few predictors (van Loo et al.,
2014a; Wardenaar et al., 2014), cross-sectional data (van Loo et al.,
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2014a; Wardenaar et al., 2014), questionnaire instead of interview-
based clinical data (van Loo et al., 2014a; Wang et al., 2014;
Wardenaar et al., 2014), a short follow-up period (Chekroud et al.,
2016; de Vries et al., 2018; Perlis, 2013), or data from women only
(van Loo et al., 2015).
In a recently published study, we developed a prediction model for
recurrence of MD in an attempt to address these previous limitations
(van Loo et al., 2018). We used prospective data, mostly derived from
structured clinical interviews, from a sample of 653 participants who
reported an episode of MD in the last year. We used a broad range of
clinical characteristics assessed at baseline to optimally predict future
episodes of MD. The resulting prediction algorithm model showed
promising prediction performance in the training data.
Before implementation in clinical practice, prediction models need
to be evaluated in new data, preferably in multiple samples re-
presenting the target population, i.e. patients who recovered from MD
(Hastie et al., 2009; Perlis, 2013). It is crucial to determine whether
estimates of prediction performance are reliable and replicable, as es-
timates derived from initial training data might be overly optimistic
due to overfitting (i.e., the model capitalizes on idiosyncratic features of
the training data) (Hastie et al., 2009). The primary aim of this study is
to validate our previously developed multivariate prediction model in
new data. Our primary research question is: how accurately does our
previously developed model predict future episodes of MD in two in-
dependent test samples? In addition, we test how well the model pre-
dicts a broader set of course-related outcomes (future episodes of gen-
eralized anxiety disorder (GAD), panic disorder, disability). This
replication study is a necessary step towards implementation in clinical
practice.
2. Method
2.1. Previously developed prediction model for recurrence of MD
2.1.1. Training sample
In data mining, multiple independent samples are commonly used
to train and test a prediction model. The ‘training sample’ is used to
train or discover a prediction model describing the relation between the
predictors and the outcome. Then, this model is tested using new data,
the ‘test sample’, to obtain reliable estimates of prediction performance
(see also Supplemental methods).
We previously developed a prediction model for recurrence of MD
based on a large number of clinical characteristics at baseline
(van Loo et al., 2018), using training data from a longitudinal study of
male-male and male-female twin pairs from the Virginia Adult Twin
Study of Psychiatric and Substance Use Disorders (VATSPSUD). This
training sample included 653 male and female twins who reported an
episode of MD (DSM-III-R) in the year prior to baseline interview, and
who were also participating in the follow-up interview which was
carried out at least one year later. All participants reported a period of
>60 days of (partial) remission or recovery (Frank, 1991), in order to
focus on MD recurrence instead of chronicity. To minimize recall bias,
we used data from participants who reported a MD episode in the last
year rather than lifetime (Supplemental Methods). This selection was
done to increase the quality of reports about the specific symptoms
during the episode of MD, the duration, and other severity indices,
which we expected to be higher for participants who recently experi-
enced an episode of MD, than participants who had an episode more
than one year ago.
2.1.2. Model discovery
In this study, we analysed a total of 70 potential risk factors using
Cox models with elastic net regularization (R-package glmnet) to predict
the outcome recurrence of MD using time-to-event data. Regularized
regression methods include a penalty for model complexity. This pen-
alty results in the selection of predictors via the shrinkage of weaker
predictor beta-coefficients towards zero. Regularized methods are
useful for studies examining large numbers of predictors as it reduces
overfitting and yields sparser models (Hastie et al., 2009).
The 70 risk factors covered characteristics of the (1) recent de-
pressive episode (e.g., specific depressive and anxiety symptoms, level
of impairment), (2) current state (age, symptom level), (3) psychiatric
history, (4) family history, (5) personality, (6) early and (7) recent
adversity, and (8) current social and economic environment.
The elastic net penalty controlled the selection and effect sizes of
predictors to increase prediction performance and model interpretation
(Zou and Hastie, 2005). The final model was selected based on minimal
prediction error as assessed in 10-fold cross-validation (Friedman et al.,
2010; Simon et al., 2011). This model retained 24 out of the 70 initial
predictors and was highly multifactorial including diverse risk factors
such as comorbid anxiety symptoms and disorders, maternal MD, and
childhood traumas (Supplemental Table 1). Prediction performance in
the training sample was good (AUC~0.75), but the model was not
evaluated in independent test data, because the sample was relatively
small to create test data.
In this previous study, we also studied sex differences in prediction
models for recurrence of MD. Since no prominent sex differences were
identified, we selected the model built on training data including both
sexes. For detailed information on the discovery phase of the prediction
model, including its predictors, and their effect sizes, see Supplemental
Table 1 and van Loo et al. (2018).
2.2. Test prediction model
2.2.1. Test samples
We used two independent test samples from VATSPSUD and the
Netherlands Study of Depression and Anxiety (NESDA) to assess the
prediction performance and generalizability of the previously derived
prediction model (van Loo et al., 2018). These studies were selected
because of their longitudinal designs and high-quality data: data were
primarily based on structured interviews administered by trained in-
terviewers, assessed a large set of the risk factors included in the pre-
diction model, and had relatively few missing observations or drop-outs
during follow-up. The study designs, samples, and data collection are
described in detail in earlier publications (Kendler and Prescott, 2006;
Penninx et al., 2008).
The first test sample combined data from the female-female twins
(FF, n = 757) and the male-male/male-female twins (MM-MF,
n= 1544) from the VATSPSUD study, but who were not included in the
original training sample used to develop the prediction model. Thus, we
created an independent test sample including 2301 Caucasian twins
who reported a lifetime episode of MD at baseline assessment
(American Psychiatric Association, 1987), and who were re-interviewed
at follow-up at least 1 year after baseline interview. Previous studies
showed that the VATSPSUD sample is broadly characteristic of the
Caucasian general population in the USA in terms of demographic
features and rates of psychopathology (Kendler and Prescott, 2006).
The second test sample was drawn from the Netherlands Study of
Depression and Anxiety (NESDA). NESDA is a longitudinal cohort study
including 2981 subjects from the Dutch general population, primary
care, and specialized mental health care, aged 18–65 at baseline as-
sessment (2004–2007). From this sample, we included 1925 subjects
who reported a lifetime episode of MD
(American Psychiatric Association, 2000) at baseline, and who were re-
interviewed approximately 2, 4, 6 or 9 years after baseline (waves 3, 4,
5, and 6).
All participants provided written informed consent, and the studies
were approved by Institutional Review Boards of VCU and VU
University Medical centre (Kendler et al., 2008; Penninx et al., 2008).
2.2.2. Assessment and imputation of predictors
Most predictors retained in the prediction model (Table 1) were
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assessed at baseline in both test samples. All 24 predictors were present
in VATSPSUD; 21 of 24 predictors were available in NESDA (Supple-
mental Table 1). Some predictors were assessed with different instru-
ments in NESDA. In these cases, items that were most equivalent to the
predictors used in VATSPSUD were selected, and if needed, transformed
or categorized to increase comparability. All predictors were assessed at
baseline, except for four predictors which were assessed during follow-
up in part of the participants. These predictors concerned childhood
sexual abuse in NESDA and VATSPSUD-FF; and maternal MD, lifetime
GAD, low marital satisfaction in VATSPSUD-MM-MF. As these pre-
dictors concerned retrospective reports, or were assessed at baseline in
the majority of the sample, we decided not to exclude these predictors
in order not to bias the prediction performance downward.
Missingness on most predictors was limited: on average 2.8% of the
values in VATSPSUD, and 9.8% in NESDA were missing (Supplemental
Table 1). Values for missing predictors were multiply imputed in 10
datasets using Multivariate Imputation by Chained Equations (R-
package mice, 20 iterations) (van Buuren and Groothuis-
Oudshoorn, 2011). All predictors needed in the prediction model were
included in these imputations; variables concerning lifetime diagnoses
of panic disorder and social phobia were used in NESDA as extra pre-
dictors in the imputation to improve imputation results (Carpenter and
Kenward, 2013).
2.2.3. Risk score for recurrence of MD
First, we applied the prediction model for recurrence of MD to 10
imputed datasets to create 10 risk scores for each subject. The risk
scores were constructed as the sum of the subject's risk factor values
multiplied by the corresponding beta weight of that risk factor (as es-
timated in the VATSPSUD-training sample, Supplemental Table 1), i.e.
the linear predictor or prognostic index (Royston and Altman, 2013).
We created a single risk score for each subject by averaging their risk
scores from each of the 10 imputed datasets.
Because multiple imputation of missing values will often not be
feasible in clinical practice, we performed a sensitivity analysis with a
risk score where missing observations were replaced by sample means.
The sample means of VATSPSUD and NESDA are provided in
Supplemental Table 1. In this case, we created one single risk score for
each subject by summing all the subject's predictor values –or sample
mean in case the value was missing– multiplied by the predictors’
corresponding beta weights. Note that this a conservative approach to
missingness which might bias downward predictive power.
2.2.4. Assessment of prediction performance
We selected several outcomes during follow-up to test the predictive
performance of the risk score. The primary outcome was any episode of
MD during follow-up, since the prediction model was trained to predict
this outcome (van Loo et al., 2018). Given that patients recovered from
MD are not only at risk of future episodes of MD, but also of anxiety
disorders and disability (Lamers et al., 2011; Moffitt et al., 2007) –the
presence of which could also inform treatment decisions on monitoring
and treatment (e.g., continuation of antidepressant medication after
recovery of MD) – we also tested the predictive value of the risk score
with secondary outcomes. These concerned GAD and panic disorder
(Kessler et al., 2005) and severe disability as assessed by the World
Health Organization Disability Assessment Schedule (WHODAS-II). All
outcomes were dichotomous (Supplemental Table 2, note that time-to-
event data were not available).
All statistical analyses were performed in R (R Core Team, 2017;
Wickham, 2009). Logistic regression models were used to estimate the
association between the risk score at baseline and the outcomes during
follow-up (R-packages stats, rcompanion) (Mangiafico, 2017;
R Core Team, 2017). Model discrimination was assessed using areas
under the receiver operating characteristic curve (AUC, R-package Epi)
(Carstensen et al., 2017; Royston and Altman, 2013).The AUC is a
measure of model discrimination or “separation”- do patients predicted
to be at higher risk exhibit higher event rates than those predicted to be
at lower risk? (Royston and Altman, 2013)
We derived two values from the AUC to facilitate interpretation of
the effect size. The success rate difference (SRD=2AUC-1) is equal to
Somers’ D or Kendall's tau and thus interpretable as a correlation
coefficient. The number needed to take (NNT=1/SRD) represents the
number that one would need to test to have one more ‘success’ (i.e.
adverse outcome) in the higher risk group than in the lower risk group
(Kraemer, 2014).
To assess the absolute risk for different levels of the risk score, both
test samples were split in quartiles and the proportion of observed
adverse outcomes for each quartile was determined.
2.2.5. Comparison of risk score with other risk factors for severe course of
illness
To further validate the prediction model, we assessed whether our
risk score outperformed other risk factors of a severe course of MD:
measures of genetic risk, environmental risk, and neuroticism.
First, we used three measures reflecting genetic risk for MD, i.e.
family history of MD, age at onset, and polygenic risk score for MD.
These measures have been shown to be associated with a more severe
course of illness (Eaton et al., 2008; Hardeveld et al., 2013a;
Kendler et al., 2005; Mistry et al., 2018; Peterson et al., 2016). Family
history of MD was assessed as the ratio of the number of first-degree
Table 1
Characteristics of the training and test samples.
VATSPSUD
training1
VATSPSUD test2 NESDA test
Sample size (n) 653 2301 1925
Demographics
Study Origin USA USA Netherlands
Predominant ancestry (%) Caucasian Caucasian N-European
Female sex (%) 34.63 53.23 68.6
Age at interview (μ, SD) 35.2 (8.8) 34.9 (8.6) 42.0 (12.4)
Years of education (μ, SD) 13.1 (2.5) 13.4 (2.5) 11.9 (3.2)
Type of sample
General population (%) 100 100 18.4





Age at onset (μ, SD) 24.8 (11.1) 22.1 (8.8) 28.4 (12.7)
Number of lifetime episodes
(μ, SD)
7.1 (25.8) 4.8 (13.6) 4.6 (9.4)
≥ 2 lifetime episodes (%) 45.6 53.4 48.0
≥ 3 lifetime episodes (%) 33.2 34.4 36.7
≥ 4 lifetime episodes (%) 26.7 23.3 28.2
Lifetime comorbidity
GAD (%) 18.4 14.0 34.6
Alcohol dependence (%) 43.3 26.7 65.4
Risk score (μ, SD)4 1.13 (0.46) 0.75 (0.35) 1.16 (0.42)
GAD, generalized anxiety disorder; μ, mean; MD, major depression; SD, stan-
dard deviation; USA, United States of America.
1The VATSPSUD training sample included data from 653 male-male/male-fe-
male twins (MM-MF) who reported an episode of MD (DSM-III-R) in the year
before baseline interview, and whose MD status in the year prior to follow-up
interview was known. We selected participants with a last year episode of MD
only, in order to reduce recall problems. For further details, we refer to
Van Loo et al. 2018.16
2The VATSPSUD test sample included data from the female-female twins (FF,
n = 757) and the male-male/male-female twins (MM-MF, n = 1544) who re-
ported a lifetime episode of MD at baseline interview (FF1/MM-MF1). The 653
subjects included in the training sample with a last year MD-episode at MF1
were excluded from this test sample.
3The percentage of women in the VATSPSUD training sample was relatively low
because this sample was drawn from a study of male-male and male-female
twins.17
4Recurrence risk score is based on prediction model for recurrence of MD (see
Methods and Supplemental Table 1).
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relatives affected with MD divided by the number of first-degree re-
latives.
We calculated a polygenic risk score for MD for 1662 NESDA par-
ticipants whose genome wide association study (GWAS) data were
available. We used GWAS summary statistics for MD publicly released
by the Psychiatric Genomics Consortium, obtained for a subset of
59,851 cases and 113,154 controls after the exclusion of data from
23andMe (Wray et al., 2018). Furthermore, since NESDA data were part
of the meta-analysis, we re-ran the meta-analysis after removal of
overlapping data (~3 K samples). LDpred was used to compute poly-
genic risk scores (Supplemental Methods 1) (Vilhjálmsson et al., 2015).
Second, we used two measures of environmental risk –early or
lifetime traumas and childhood sexual abuse– which are also associated
with a more severe course of illness (Gopinath et al., 2007;
Hardeveld et al., 2013b; Paterniti et al., 2017). Third, we assessed the
association between the risk score and the personality trait neuroticism.
Neuroticism strongly reflects liability for MD (Jeronimus et al., 2016),
and is associated with a more severe course of MD (Xia et al., 2011). For
details about how these risk factors were assessed, we refer to Sup-
plemental Table 2.
We calculated Pearson's correlation coefficient between our risk
score and these other risk factors, and we determined the AUC's of the
other risk factors for all adverse outcomes.
3. Results
3.1. Sample characteristics
On average, participants in the test sample from NESDA had a
higher risk score for recurrence of MD at baseline than participants in
the VATSPSUD test sample (Table 1). NESDA participants also reported
more often lifetime episodes of GAD and alcohol dependence at base-
line. This may reflect differences in disease severity due to differences
in sample ascertainment. Whereas VATSPSUD is based on birth records
of twins in Virginia (Kendler and Prescott, 2006), NESDA sampled from
the general population, primary care, and specialized mental health
care (Penninx et al., 2008). In addition, NESDA included a large pro-
portion of subjects with current depressive or anxiety disorders, whereas
in VATSPSUD, 653 cases with last year/current MD were excluded from
the test sample since they were included in the training sample drawn
from VATSPSUD. The larger proportion of participants with current/
recent episodes of MD (instead of lifetime) in NESDA might also explain
the similarity between the risk score in the test sample from NESDA and
the training sample from VATSPSUD, which included exclusively sub-
jects with a last year MD episode (Table 1).
As expected, there were high rates of co-occurrence between the
different outcomes (Table 2). Correlations between MD at follow-up
and GAD, panic disorder, and severe disability at follow-up ranged
between 0.34 and 0.76.
3.2. Prospective prediction performance
In both test samples, the risk score significantly predicted future
episodes of MD, and also the other adverse course-related outcomes,
viz. episodes of GAD, panic disorder, and disability (Table 3). Despite
the fact that the risk score was specifically trained to predict MD re-
currence, its associations with future episodes of MD, GAD, panic dis-
order, and disability were equally strong. A standard deviation (SD)
increase in risk score corresponded with a double risk of these adverse
outcomes (mean OR=2.1). In addition, the AUC's for future episodes of
MD (range 0.68–0.73) were comparable with AUC's for the other out-
comes (range 0.65–0.78) as indicated by the overlapping 95% con-
fidence intervals.
Prediction performance for future episodes of MD in both test
samples was comparable to the performance in the training sample
(AUC's 0.68–0.73 versus AUC 0.75; confidence intervals were over-
lapping), indicating that there was little overfitting of the prediction
model in the training data. This showed that the predictive performance
of this model was not specific to our first study, but that the model also
predicted adverse outcomes of MD across samples from different sub-
populations, two different countries, in which different measurement
procedures were used.
Using sensitivity analyses, we assessed to what extent prediction
performance decreased when multiple imputation was not used to
construct the risk score, but missing values were replaced by sample
means, because in clinical practice multiple imputation will often not
be feasible. Prediction performance was very comparable for this al-
ternative risk score, i.e. AUC's were at most 0.01 attenuated
(Supplemental Table 3).
Dividing participants in quartiles based on their risk score, subjects
in the lower risk groups consistently reported fewer adverse outcomes
than individuals in the higher risk groups (Fig. 1). ROC-curves showed
that the optimal cutpoint of the risk score (i.e., resulting in the max-
imum sum of sensitivity and specificity) for the risk score was ~0.8 in
VATSPSUD and ~1.0 in NESDA, resulting in a mean sensitivity of 74%
(range 65–82) and mean specificity of 60% (range 46–76) across the
different outcomes (Supplemental Fig. 1). The mean negative predictive
value was 63% (range 16–83) and the mean positive predictive value
was 15% (range 4–51). This means that at the optimal cutpoint, the
score performs better in detecting the true negatives than the true
Table 2








MD 0–1 year 16.9 5.0
GAD 0–1 year 0.76 6.1
Panic disorder 0–1 year 0.46 0.50
(b). NESDA
MD 0–9 year GAD 0–9 year Panic disorder 1–2 year WHODAS ≥40 2 year WHODAS ≥40 6 year
MD 0–9 year 8.0 3.2 6.6 7.2
GAD 0–9 year 0.60 3.8 3.9 4.3
Panic disorder 1–2 year 0.34 0.43 2.2 2.1
WHODAS ≥40 2 year 0.52 0.47 0.26 10.4
WHODAS ≥40 6 year 0.52 0.48 0.24 0.70
GAD, generalized anxiety disorder; MD, major depression; WHODAS, World Health Organization Disability Assessment Schedule.
Rates of co-occurrence or comorbidity in VATSPSUD (n = 2301) and NESDA (n = 1925) as indexed by tetrachoric correlations (lower diagonal) and odds ratios
(upper diagonal).
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positives in a population. This can be attributed to the relatively low
prevalence of some of the outcomes. If outcomes are rare (e.g., panic
disorder occurred in only 7% of VATSPSUD participants), diagnostic
tests will more often result in false positives, and less often in false
negatives. From a clinical standpoint, a negative test result could in this
case be more valuable than a positive test result (e.g., a negative test
result could support a decision to reduce antidepressant use).
3.3. Comparing the model with other risk factors for severe course of illness
We compared the prediction performance of our risk score with
several measures of genetic risk, environmental risk, and neuroticism,
which are well-known risk factors for a severe course of MD. We did
this to assess to what extent the more complex risk score outperformed
these simpler risk factors. Three of these risk factors were included as a
predictor in our risk score (family history, traumas, childhood sexual
abuse), the other three risk factors (age at onset, polygenic risk score for
MD, neuroticism) were not.
All these risk factors for a severe course of illness were significantly
correlated with our risk score in the expected direction (Supplemental
Table 4, all P-values<0.002). Subjects with a higher risk score tended
to have more first-degree relatives with MD, a higher polygenic risk for
MD, an earlier age at onset, higher neuroticism scores, and reported a
higher number of traumas and a history of childhood sexual abuse.
Neuroticism was particularly highly correlated with the risk score
(r~0.5).
The risk score predicted the outcomes more accurately (AUC's
0.65–0.78) than logistic regression models based on one of the other
risk factors. Prediction performance of the following risk factors -family
history of MD, age at onset, polygenic risk score for MD, and childhood
sexual abuse- were all in the same range (AUC's ~0.5–0.6), and lifetime
traumas performed slightly better (AUC's 0.55–0.66) (Table 4). How-
ever, the model including neuroticism only predicted the outcomes
almost as accurately as our risk score (AUC's 0.64–0.76). The con-
fidence intervals of the AUC's were overlapping for most outcomes,
except for episodes of MD and GAD in VATSPSUD (Supplemental
Table 5). For these two outcomes, the risk score had a significantly
higher AUC. Of note, neuroticism was not included in our risk score.
While it was included in the model discovery phase, it was not retained
in the elastic net penalized model (van Loo et al., 2018), which could be
due to multicollinearity between neuroticism and the other predictors.
Because of the relatively strong prediction performance of neuroti-
cism, we performed post hoc analyses to investigate whether neuroti-
cism could further enhance prediction performance of the risk score.
We performed an unpenalized Cox regression analysis including both
our risk score and neuroticism as independent variables to predict MD
recurrence in the training data (VATSPSUD, n = 653) (van Loo et al.,
2018). In this model, our risk score significantly predicted MD recur-
rence (HR 2.1, CI 1.8–2.4) but neuroticism's effect attenuated to not
significant (HR 0.9, CI 0.8–1.1). The addition of neuroticism to the risk
score did not improve prediction performance– AUC's based on this
model were similar to or lower than these based on the risk score alone.
4. Discussion
4.1. Principal findings
We tested a data mining algorithm for predicting future episodes of
MD in subjects with lifetime MD using baseline clinical characteristics.
The model consistently predicted future episodes of MD in two in-
dependent test samples, despite differences in sample composition,
study design and assessment of predictors. In addition, the model pre-
dicted future episodes of GAD, panic disorder, and disability compar-
ably. Furthermore, the algorithm outperformed several known risk
factors for a more severe course of illness, viz. measures of genetic risk,
and environmental risk. Only neuroticism predicted the adverse
Table 3
Risk score predicting psychopathology and disability during follow-up.
Sample OR1 95% CI AUC 95% CI SRD2 NNT2 N3 mean4
Any MD
MD 0–1 year5 VATSPSUD 2.1 1.8–2.3 0.73 0.69–0.76 0.45 2.2 1930 0.16
MD 0–2 year NESDA 1.9 1.7–2.2 0.68 0.66–0.71 0.37 2.7 1638 0.46
MD 0–9 year NESDA 2.3 2.0–2.7 0.72 0.69–0.75 0.44 2.3 1522 0.74
Any anxiety disorder
GAD 0–1 year5,6 VATSPSUD 2.5 2.2–2.9 0.78 0.75–0.81 0.56 1.8 1929 0.13
GAD 0–2 year NESDA 2.0 1.8–2.4 0.70 0.67–0.74 0.40 2.5 1638 0.13
GAD 0–9 year NESDA 2.3 2.0–2.6 0.73 0.70–0.75 0.45 2.2 1264 0.34
Panic disorder 0–1 year5 VATPSUD 2.0 1.6–2.5 0.72 0.63–0.80 0.43 2.3 701 0.07
Panic disorder 1–2 year5 NESDA 1.6 1.4–1.9 0.65 0.61–0.68 0.29 3.4 1638 0.16
Disability
WHODAS ≥40 2 year NESDA 2.3 2.0–2.7 0.72 0.69–0.76 0.45 2.2 1091 0.24
WHODAS ≥40 6 year NESDA 2.3 1.9–2.7 0.73 0.69–0.77 0.46 2.2 862 0.19
AUC, area under the receiving operating characteristic curve; CI, confidence interval; FU, follow-up; GAD, generalized anxiety disorder; MD, major depression; N,
number; NNT, number needed to take; OR, odds ratio; SRD, success rate difference; WHODAS, World Health Organization Disability Assessment Schedule.
This table represents the estimated associations between the recurrence risk score at baseline (as described in Supplemental Table 1) and several adverse outcomes
during follow-up. The strength of association was tested using logistic regression analyses in which the standardized recurrence risk score (M = 0, SD=1) was the
independent variable, and the measures of MD, anxiety, and disability were the dependent variables. All outcomes were binary; psychiatric disorders were coded as
“1” if the subject reported at least one episode in the time interval. Disability was coded as “1” if the participant's level of disability was high (WHODAS>40,
corresponding roughly with the top 25% in NESDA). Years indicate the approximate number of years after baseline assessment (e.g., 0–2 years concerns the first two
years after baseline, etc.). For ROC-curves see Supplemental Figure 1.
1All odds ratios are highly significant with P-values < 3 × 10−9 (Bonferroni corrected alpha 0.05/21 = 0.002).
2 Success rate difference (SRD) equals 2AUC-1 (equal to Somers’ D or Kendall's tau and thus interpretable as a correlation coefficient). Number needed to take (NNT)
equals 1/SRD, and represents the number one needed to sample from the subgroup with the higher risk to have one more ‘success’ (i.e. adverse outcome) than the
lower risk group.
3Number (N) of subjects with available data on the dependent variable.
4Proportion of subjects reporting this outcome.
5Outcome assessed in the 12 months prior to interview wave(s).
6In VATSPSUD, we tested the association of the recurrence risk score with episodes of GAD with a duration of ≥1 month instead of ≥6 months in the year prior to
interview, because only 4% of cases reported GAD with a duration ≥6 months, which might limit reliability of estimated associations.
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outcomes with nearly equal performance. However, prediction was not
improved when we combined the risk score and neuroticism.
4.2. Scientific and clinical relevance
First, estimates of prediction performance were similar across two
differently ascertained test samples. This indicates that the combination
of risk factors predicting future episodes of MD are to some extent
shared rather than being unique across subjects with MD sampled from
the general population, primary care, and specialized mental health
care, across subjects from different countries, twins vs. non-twins, and
measured with different procedures. This is a promising finding for
clinical practice since a prediction model derived in one sample could
be relevant for clinical populations, rather than being restricted to the
training sample used to develop the model.
Second, the model predicted a broader range of adverse outcomes
than it was originally developed for: it did not only predict future
episodes of MD but also episodes of anxiety disorders and disability.
Thus, the model could give clinicians an estimate of the risk on multiple
outcomes instead of only one, which might facilitate treatment deci-
sions. For example, one could think of decisions on the intensity of
monitoring, or continuing treatment in patients who recovered from
depression to prevent future episodes of MD or anxiety disorders
(Coplan et al., 2015).
Third, the model predicted future episodes of MD, anxiety disorders,
and disability very similarly. Partly, this was expected because of the
high rates of co-occurrence between MD, anxiety disorders and severe
disability, and the overlap in their risk factors (Kendler et al., 2011).
However, it was surprising how similar the model predicted across
these outcomes. Future studies are needed to investigate whether more
specific prediction models can be identified with larger training sam-
ples.
4.3. Relation to previous studies
In previous studies using independent test data, estimates of pre-
diction performance for models predicting course of MD were quite
similar. In our study, the average AUC across future episodes of de-
pression, anxiety, and disability was 0.71, whereas in previous studies
predicting course-related outcomes in MD the AUC ranged from 0.63 to
0.76 (for ≥12 weeks follow-up) (Chekroud et al., 2016; de Vries et al.,
2018; Kessler et al., 2016; Perlis, 2013; Wang et al., 2014). Interest-
ingly, estimates of prediction performance for prediction models in
other medical disciplines are not very different. For instance, similar
AUC's have been found for instance in models predicting mortality after
myocardial infarction (0.75–0.77) (van Loo et al., 2014b), other out-
comes in cardiology (0.7–0.8) (Siontis et al., 2012), melanoma
(0.7–0.8) (Usher-Smith et al., 2014), or bleeding when using anti-
platelet therapy after percutaneous coronary intervention (0.64)
(Yeh et al., 2016).
Despite its potential relevance for clinical practice, few previous
studies assessed the predictive value of a model for a wider range of
outcomes than the model was original trained for. Only one study ex-
ternally validated one data mining risk score across multiple outcomes:
MD persistence and chronicity, hospitalization for depression, at-
tempted suicide, disability due to depression at time (Kessler et al.,
2016). Similar to our study, this risk score predicted these different
multiple outcomes (AUC's 0.63–0.76), but its predictive value for
Fig. 1. Observed outcomes for different risk groups.
DIS, disability (WHODAS>40); GAD, generalized anxiety disorder; MD, major depression; panic, panic disorder; WHODAS, World Health Organization Disability
Assessment Schedule; y, year.
In each external validation sample, subjects were stratified in quartiles based on their recurrence risk score: quartile 1 includes 25% of subjects with the lowest
recurrence risk scores and quartile 4 includes the 25% of subjects with the highest scores. The subjects in quartiles 2 and 3 had intermediate scores. The y-axis shows
the proportion of subjects reporting the outcome during follow-up. (a) Presents the results of the VATSPSUD test sample, (b) presents the results of the NESDA test
sample. The number of cases (N) with present data for each outcome are described in Table 3.
Values of unstandardized risk score in VATSPSUD: quartile 1 [0.17–0.51]; quartile 2 (0.51–0.68]; quartile 3 (0.68–0.92]; quartile 4 (0.92–2.3].
Values of unstandardized risk score in NESDA: quartile 1 [0.22–0.83]; quartile 2 (0.83–1.11]; quartile 3 (1.11–1.49]; quartile 4 (1.49–2.2].
H.M. van Loo, et al. Journal of Affective Disorders 276 (2020) 945–953
950
anxiety disorders was not assessed, so we cannot compare these results.
Our risk score performed only modestly better than neuroticism in
predicting adverse outcomes in MD. However, the effect of neuroticism
was attenuated to nonsignificant when added to the risk score in a
multiple predictor model, while our risk score remained strongly pre-
dictive. Two previous studies found a similar attenuation of neuroti-
cism's effect to predict recurrence of MD in a model including multiple
predictors such as stressful life events and childhood traumas
(Gopinath et al., 2007; Hardeveld et al., 2013b). One study found that
neuroticism did not predict MD recurrence even in a univariate context
(Hardeveld et al., 2013a). Given the inconsistent findings, future stu-
dies are warranted to investigate whether neuroticism is a consistent
predictor of MD recurrence, and how it compares to our risk score.
4.4. Strengths and limitations
First, although our model's prediction performance was comparable
to that of other models predicting course of MD, and other medical
conditions, its performance is moderate (AUC~0.7), with relatively low
positive predictive values for some of the rare outcomes. The model also
needs information on 24 predictors, which may limit its value for
clinical practice. Future studies are needed to assess whether the model
can be improved by using larger training samples, other types of sta-
tistical learning techniques (Chekroud et al., 2016), or other types of
data such as neuro-imaging, biomarkers, and molecular genetic data
(Gillan and Whelan, 2017). However, the fact that our model ex-
clusively utilizes readily available clinical information also is a strength
as this reduces its associated costs and burden to patients.
Second, despite our study showed consistent prediction perfor-
mance in two different independent test samples from different popu-
lations, prediction might be different for specific subgroups of patients.
How well does this model predict course of MD in hospitalized patients,
or in patients from different cultures? Furthermore, are results gen-
eralizable to situations in which less high-quality baseline data are
available? Partly, this study showed that not all predictors need to be
available or assessed with the exact same instruments –which promotes
its applicability in clinical practice– but more work is needed to confirm
this.
Third, not all our outcomes or predictors were optimally assessed.
For instance, outcomes were assessed over the course of several years,
instead of over a period of months, or decades. The latter would have
provided more fine-grained information to test the risk score's predic-
tion performance on the short and long term. More longitudinal studies
are needed to collect these data. In addition, the polygenic score for MD
only explains a limited percentage of the variance of MD (Wray et al.,
2018), and different genetic variants might be implicated in MD onset
than in MD recurrence.
Fourth, calculating the risk score by hand in clinical practice is labor
intensive. We are working on a digitalized version of this prediction
model, which facilitates implementing and testing this algorithm in
clinical samples.
Fifth, in all probabilistic decision tools, the interpretation of prob-
abilistic estimates is challenging. For instance, low probabilities are
generally overrated, whereas high probabilities are underrated
(Kahneman and Tversky, 1979). Thus, it should be carefully studied
whether the application of these probabilistic decision support tools
indeed improves clinical decision making in randomized controlled
trials (Gillan and Whelan, 2017).
5. Conclusion
A prediction model based on 24 clinical characteristics consistently
predicted multiple outcomes related to a more severe course of MD.
Future studies are needed to test whether this risk prediction tool can
serve as an extra source of information to differentiate high-risk from
low-risk patients in clinical practice. The final aim would be to leverage
the opportunities of data mining to improve insight into individual
disease risk, and tailor treatment decisions to the individual patient.
Table 4
AUCs of the risk score compared with competing predictors.
Sample AUC
Risk score FH MD1 AAO2 PRS MD3 Neur7 Traumas4 CSA
Any MD
MD 0–1 year5 VATSPSUD 0.73 0.58 0.56 n.a. 0.65 0.56 0.52
MD 0–2 year NESDA 0.68 0.55 0.55 0.53 0.70 0.60 0.52
MD 0–9 year NESDA 0.72 0.57 0.54 0.53 0.74 0.61 0.52
Any anxiety disorder
GAD 0–1 year5,6 VATSPSUD 0.78 0.60 0.55 n.a. 0.64 0.56 0.56
GAD 0–2 year NESDA 0.70 0.52 0.51 0.53 0.66 0.58 0.50
GAD 0–9 year NESDA 0.73 0.53 0.53 0.55 0.73 0.61 0.52
Panic disorder 0–1 year5 VATPSUD 0.72 0.58 0.49 n.a. 0.76 0.55 0.61
Panic disorder 1–2 year5 NESDA 0.65 0.55 0.55 0.54 0.64 0.54 0.52
Disability
WHODAS ≥40 2 year NESDA 0.72 0.51 0.54 0.53 0.74 0.66 0.54
WHODAS ≥40 6 year NESDA 0.73 0.56 0.52 0.51 0.72 0.64 0.53
AAO, age at onset; AUC, area under the receiving operating characteristic curve; CSA, childhood sexual abuse; MD, major depression; N, number; n.a., not available;
PRS, polygenic risk score.
This table presents the AUC's of logistic regression models.
1Ratio of family members with MD, calculated by dividing the number of first-degree relatives with MD by the number of first-degree relatives.
2Age at onset of MD (years). To increase the comparability with the other predictors, we multiplied the age at onset by−1 to estimate its AUC, because a lower age at
onset is associated with a higher risk of adverse outcomes.
3Polygenic risk score for MD; GWAS-data are not available for VATSPSUD.
4Traumas during lifetime in VATSPSUD; traumas during childhood in NESDA.
5Outcome assessed in the 12 months prior to interview wave(s).
6In VATSPSUD, we tested the association of the recurrence risk score with episodes of GAD with a duration of ≥1 month instead of ≥6 months in the year prior to
interview, because only 4% of cases reported GAD with a duration ≥6 months, which might limit reliability of estimated associations.
7 Because of the similarity of the AUC's for the risk score and neuroticism, 95%-confidence intervals were calculated for the AUC's of neuroticism (see Supplemental
Table 5). All AUCeCI's of neuroticism were overlapping with the AUCeCI's of the risk score, except for MD 0–1 year VATSPSUD: AUC 0.65 (CI 0.61–0.68) and GAD
0–1 year VATSPSUD: AUC 0.64 (CI 0.59–0.68). Confidence intervals of the risk score are presented in Table 3.
For more details on the outcomes or competing predictors, we refer to Supplemental Table 2.
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